The "Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2025" has been added to ResearchAndMarkets.com's offering.

The report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners. Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals. Fully revised and updated, the report provides details of co-development deals from 2016 to 2025.

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse co-development deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report offer a foundational understanding of co-development dealmaking and related business activities. Starting with an introduction, the report then covers trends and merits of co-development deals in Chapter 2. Chapter 3 outlines the deal structures while Chapter 4 reviews leading deals based on headline value. Chapter 5 lists the top 25 active dealmaker companies, providing links to detailed records and contracts. Finally, Chapter 6 compiles deals by company, therapy, technology, and industry type, offering in-depth insights into the agreed terms.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in co-development dealmaking

2.1. Introduction

2.2. Definition of co-development deal

2.3. Trends in co-development deals since 2016

2.3.1. Co-development dealmaking by year, 2016-2025

2.3.2. Co-development dealmaking by phase of development, 2016-2025

2.3.3. Co-development dealmaking by industry sector, 2016-2025

2.3.4. Co-development dealmaking by therapy area, 2016-2025

2.3.5. Co-development dealmaking by technology type, 2016-2025

2.3.6. Co-development dealmaking by most active company, 2016-2025

2.4. Reasons for entering into co-development partnering deals

2.5. The future of co-development deals

Chapter 3 - Overview of co-development deal structure

3.1. Introduction

3.2. Co-development agreement structure

Chapter 4 - Leading co-development deals

4.1. Introduction

4.2. Top co-development deals by value

Chapter 5 - Top 25 most active co-development dealmakers

5.1. Introduction

5.2. Top 25 most active co-development dealmakers

Chapter 6 - Co-development deals including contracts directory

6.1. Introduction

6.2. Co-development deals with contracts 2016-2025

Deal directory

• Deal directory - co-development dealmaking by companies A-Z
• Deal directory - co-development dealmaking by therapy area
• Deal directory - co-development dealmaking by technology type

Companies Featured

• 1ST Biotherapeutics
• 2seventy bio
• 3B Pharmaceuticals
• 3DMed
• Abbisko Therapeutics
• Abbott Laboratories
• Abbvie
• AbCellera Biologics
• Acepodia
• Acuitas Therapeutics
• Aduro BioTech
• Affini-T Therapeutics
• AGC Biologics
• Agios Pharmaceuticals
• AIkido Pharma
• Ajinomoto
• Alector
• Allele Biotechnology and Pharmaceuticals
• Amgen
• Ampio Pharmaceuticals
• Astellas Pharma
• Ascentage Pharma
• ASLAN Pharmaceuticals
• AstraZeneca
• Atara Biotherapeutics
• Axovant Gene Therapies
• Beam Therapeutics
• BeiGene
• Bayer
• Beam Therapeutics
• BioAtla
• Biogen
• BioNTech
• BioNxt Solutions
• Boehringer Ingelheim
• BridgeBio Pharma
• CanSino Biologics
• Cedars-Sinai Medical Center
• Centessa Pharmaceuticals
• Centrexion Therapeutics
• China National Biotech Group (CNBG)
• CureVac
• Daiichi Sankyo
• Denali Therapeutics
• DotBio
• Dynavax Technologies Corporation
• GE Healthcare
• Genentech
• Gilead Sciences
• GREENLIGHT BIOLOGICS
• Janssen Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/c5gf47

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250721705032/en/